Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Biolidics, IncellDx Sign Distribution Agreement

Biolidics, IncellDx Sign Distribution Agreement

Dec 18, 2019
|
staff reporter

NEW YORK – IncellDx said on Wednesday that that it has signed an agreement with Singapore-based Biolidics to distribute its IncellDx bioINK PD-L1 CTC Core Kit. 

As part of the agreement, Biolidics will distribute the kit with Biolidics' ClearCell FX1 system. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15
Featured Webinar

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

Sponsored by
Agena Bioscience

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

Oct
20
Featured Webinar

Crystal Digital PCR for Accurate Chimerism Monitoring after Stem Cell Transplantation

Sponsored by
Stilla

This webinar will discuss a new method that relies on Crystal digital PCR from Stilla Technologies to monitor chimerism in patients after stem cell transplantation, which is a key part of surveillance for impending clinical relapse.

What's Popular?

In Cancer

  1. Sema4, Janssen Partner on Patient Identification for Cancer Clinical Trials

  2. Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

  3. Angle Files De Novo FDA Submission for CTC Collection Device in Breast Cancer

  4. Spain's Universal Diagnostics Bets on Cell-Free DNA Methylation for Early-Stage Cancer Detection

    Premium

  5. Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.